health - "medicine"

Jun 20, 2008 - Merck & Co., Inc. today provided an update on the regulatory status in the United States of its investigational medicines MK-0524A and MK-0524B for the treatment of primary hypercholesterolemia ...

Mumbai, June 20: US drug authorities have given the green signal to Glenmark Pharmaceuticals to market and distribute the high blood pressure medicine, Trandolapril.

The results of a major international clinical trial coordinated by the Montreal Heart Institute were reported in the New England Journal of medicine. The Atrial Fibrillation and Congestive Heart Failure Trial (AF-CHF) was a prospective, multicentre project involving patients with heart failure and atrial fibrillation. Heart failure is an important cause of death in the population and associated atrial fibrillation (a very common heart rhythm disorder) further increases the risks.

Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced three presentations at the Society of Nuclear medicine (SNM) 55th Annual Meeting on preclinical data supporting its Trofex program for the detection, staging and monitoring of prostate cancer. The presentations described the synthesis, production and preclinical profile of two lead candidate compounds, MIP-1072 and MIP-1095.

14 Member Organisations* of the European Science Foundation have launched a key initiative to keep Europe at the forefront of regenerative medicine; broadly defined as the development of stem cell therapies to restore lost, damaged, or ageing cells and tissues in the human body.Stem cells are the body's 'master cells' that have not yet been programmed to perform a specific function.

Merck KGaA announced that it has submitted an application to the European Medicines Agency (EMEA) to broaden the use of the targeted therapy Erbitux® (cetuximab) to include 1st-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

GE Healthcare launched the company's next-generation applications to expand the capabilities of the company's SPECT/CT flagship: Infinia Hawkeye 4. The new software applications, offered as Volumetrix Suite, were on display June 14-18 at the 55th annual meeting of the Society of Nuclear medicine.'Only GE brings the power of 3C imaging to nuclear medicine with Volumetrix Suite.

Gamma Medica-Ideas and GE Healthcare announced at the 55th annual meeting of the Society of Nuclear medicine, that GE Healthcare will be the exclusive distributor of Gamma Medica-Ideas' pre-clinical imaging products effective July 1, 2008. Pre-Clinical imaging plays a key role in new pharmaceutical therapeutic development by allowing researchers to visualize the structure, function and response of laboratory animals in vivo.